undefined
\
Nov 10, 2026
Your patient is 28 weeks pregnant, on the maximum dose of sertraline, and still scoring a 16 on the PHQ-9. She's asking what comes next.
You don't have the luxury of "refer to psychiatry" as your answer.
The AANP agrees.
Recent exam feedback describes exactly this scenario: pregnant or postpartum patients with persistent anxiety or depression despite maximized first-line treatment.
Every answer choice is a pharmacologic next step.
Switch the medication.
Add a second agent.
Choose a specific drug.
If that makes you uncomfortable, you're not alone. But you need to know the algorithm.
The Foundation: ACOG Clinical Practice Guideline No. 5
The decision framework lives in ACOG's 2023 guideline on mental health conditions during pregnancy and postpartum.
The single most important recommendation: do not withhold or discontinue medications solely because of pregnancy or lactation.
That's a strong recommendation, and it changes the entire framing of the conversation.
Before any pharmacologic step:
assess substance use
screen for bipolar disorder (MDQ or CIDI)
rule out medical causes (TSH, CBC, B12, vitamin D, folate)
Psychotherapy is first-line for mild-to-moderate depression. But when first-line treatment is already optimized and symptoms persist, the next move is yours to make.
The Stepwise Algorithm in Practice
Dose optimization comes first.
If your patient tolerates the medication with minimal side effects but hasn't reached remission, titrate up. In pregnancy, physiologic changes (increased blood volume, hepatic metabolism, renal clearance) often require higher doses than you'd use in the general population. Anxiety in particular tends to need the upper end of the therapeutic range.
If the current agent fails at maximum dose, the next step depends on the clinical picture:
Side effects present? Switch to a different SSRI or cross-class to an SNRI.
Partial response with good tolerability? Consider augmentation.
Prominent somatic anxiety or GAD features? Venlafaxine is your cross-class switch.
OCD-spectrum symptoms? Fluvoxamine is preferred.
Depression with fatigue and low motivation? Bupropion can help, but it won't touch anxiety.
The key distinction that the exam tests:
switching is for failure or intolerance
augmentation is for partial response when the patient tolerates the current agent
Zuranolone: The New Agent to Know
Zuranolone (Zurzuvae) earned FDA approval in August 2023 as the first oral treatment specifically indicated for postpartum depression. It's a neuroactive steroid, a positive allosteric modulator of GABA-A receptors, and it works differently from SSRIs and SNRIs.
The prescribing details:
50 mg once daily for 14 days
taken in the evening with a fatty meal (400 to 1,000 calories, 25 to 50% fat)
dose reductions apply for
somnolence
severe hepatic impairment
eGFR below 60
strong CYP3A4 inhibitor co-use
Three facts you need cold:
The boxed warning is about driving impairment. Patients may not recognize their own impairment. No driving for at least 12 hours after a dose.
Effective contraception is required during treatment and for one week after.
If the 14-day course doesn't work, do not repeat it. Move to other management options.
Zuranolone can be combined with an SSRI or SNRI.
It replaced brexanolone (Zulresso), which was withdrawn from the market in January 2025 after its 60-hour IV infusion model proved impractical.
The Augmentation Question: Why Buspirone Keeps Showing Up
When residual anxiety persists on a maximized SSRI, buspirone is the most commonly tested augmentation choice on the AANP exam. It's a 5-HT1A partial agonist, it's not a controlled substance, and it can be added to an SSRI without serotonin syndrome risk.
Buspirone is not a PRN medication. It requires two to four weeks for onset, just like an SSRI. Start at 7.5 mg twice daily, increase by 5 mg every two to three days, and set expectations clearly with your patient.
If you need an immediate bridge for severe anxiety, short-course lorazepam (one to two weeks) is the guideline-supported option. Lorazepam is preferred among benzodiazepines in pregnancy (lower placental passage) and in lactation (low milk levels). Taper by 25% to 50% weekly once the SSRI or SNRI takes effect. Avoid alprazolam.
Build Your Confidence Before Exam Day
Perinatal psychopharmacology is one of those topics where clinical reasoning matters more than memorization. You need the algorithm, the safety data, and the confidence to pick the right next step.
FNP Mastery's practice questions are built around exactly these decision points. If you want to work through perinatal mental health scenarios before you sit for the AANP, the app is a good place to start.
Frequently Asked Questions
Is it safe to start an SSRI in the first trimester?
Yes.
ACOG's 2023 guideline gives a strong recommendation against withholding antidepressants due to pregnancy alone. A large Medicaid cohort found no increased infant cardiac malformation risk for SSRIs or SNRIs in the first trimester. The risks of untreated depression (preterm birth, poor prenatal care, postpartum escalation) are well established. A previously effective agent from any class is preferred for reinitiation.
Should I taper an SSRI or SNRI before delivery to prevent neonatal adaptation syndrome?
No.
Tapering before delivery does not reduce neonatal adaptation syndrome risk and significantly increases relapse risk. ACOG recommends continuing the effective dose through delivery. Plan for a hospital delivery when the patient is on SSRIs or SNRIs at term, and counsel the family that neonatal symptoms (jitteriness, feeding difficulty, irritability) typically resolve within two weeks.
Can I prescribe zuranolone during pregnancy?
No.
Zuranolone is indicated only for postpartum depression, and the labeling warns of possible fetal harm. Effective contraception is required during the 14-day course and for one week after. There are no clinical trial data on use during pregnancy.
Which SSRIs are preferred during breastfeeding?
Sertraline, paroxetine, and fluvoxamine are favored because of low milk transfer.
Monitor breastfed infants for sedation and poor feeding. SNRIs are also compatible with breastfeeding, though the evidence base is smaller. The goal is to keep the mother on an effective regimen rather than switching agents solely for lactation.
When should I refer to psychiatry instead of managing pharmacotherapy myself?
Refer when you've reached Step 5 of the algorithm:
the patient has failed or partially responded to two adequate trials (including at least one cross-class switch or augmentation)
when there's diagnostic complexity (comorbid bipolar, PTSD, psychosis, active substance use)
when the patient needs a medication you're not comfortable prescribing.
Perinatal psychiatry access programs like MCPAP for Moms (855-666-6272) offer real-time provider consultation.
Sources:
ACOG Clinical Practice Guideline No. 5 (June 2023)
UW PERC Perinatal Anxiety Care Guide (June 2025)
FDA Zuranolone Approval (August 2023)
Federal Register: Brexanolone Withdrawal (March 2025)
